Kenvue stock gains as Kimberly-Clark acquisition premium supports valuation
Published on 09/18/2026 at 15:40 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Kenvue stock (ISIN US49177J1025) traded at USD 17.89 on the New York Stock Exchange as of September 18, 2026, with the Kimberly-Clark acquisition terms still implying a notable premium to that level. According to Yahoo Finance on September 18, 2026, the stock stood at USD 17.89 during market hours, while earlier deal terms suggested an implied value near USD 21.01 per share.
Acquisition by Kimberly-Clark shapes Kenvue stock story
The central catalyst for Kenvue stock in 2026 is the planned acquisition by Kimberly-Clark, which continues to anchor expectations for a takeover premium. As 24/7 Wall St reported on September 18, 2026, Kimberly-Clark agreed in November 2025 to acquire Kenvue in a mixed cash-and-stock transaction that valued Kenvue at approximately USD 48.7 billion. Under the terms outlined there, Kenvue shareholders would receive USD 3.50 in cash plus 0.14625 Kimberly-Clark shares for each Kenvue share, resulting in an implied total value of roughly USD 21.01 per Kenvue share at the time of announcement.
That deal valuation matters directly for Kenvue stock because it offers investors a concrete comparison point against the current market price. With Kenvue at USD 17.89 as of September 18, 2026 and the original deal implying around USD 21.01 per share, the stock trades at about USD 3.12 below the initial reference value, indicating a discount of roughly 14.8 percent versus that benchmark based on those terms. The transaction is expected to close in the second half of 2026, and according to 24/7 Wall St, shareholders would receive a premium to the prevailing market price once the deal is completed, though the final value depends on Kimberly-Clark's share price at closing.
Dividend yield and latest quarterly figures
Beyond the takeover story, Kenvue stock offers an income angle that is quantified by its forward dividend and yield. According to Yahoo Finance on September 18, 2026, Kenvue's forward annual dividend is USD 0.84 per share, which translates into a forward dividend yield of 4.71 percent at the prevailing share price. The same data set indicates that Wall Street values the consumer health group at about 21 times earnings, reflecting the market's view of its brand strength and cash generation capacity.
From an operating perspective, the most recent quarterly figures give investors a clearer picture of the business underpinning Kenvue stock. As per Yahoo Finance, Kenvue generated revenue of USD 3.96 billion in Q2 fiscal year 2026 and earnings of USD 456 million for the same period, corresponding to a profit margin of 11.53 percent. The earnings line in that data shows an actual Q2 FY26 earnings per share of USD 0.31 versus an estimate of USD 0.319, meaning reported EPS came in slightly below the consensus expectation by USD 0.009 per share, a modest shortfall that still leaves the company solidly profitable.
Analyst view and valuation benchmarks
Analyst sentiment on Kenvue stock is captured in both ratings and price targets that help frame market expectations. According to Yahoo Finance, the average analyst price target for Kenvue stands at USD 19.50, compared to a current share price of USD 17.89 on September 18, 2026. That implies upside of around USD 1.61 per share or roughly 9.0 percent if the stock were to move to the mean target. A more detailed narrative from Simply Wall St on September 17, 2026 notes that fair value estimates cluster around USD 19.50 and describes Kenvue as potentially 9 percent undervalued relative to this narrative fair value reference.
Rating distributions reinforce the view of Kenvue stock as neither a clear consensus buy nor an outright sell. As MarketBeat summarized on September 18, 2026, Kenvue currently carries an average rating of Hold from Wall Street analysts, with a consensus target price of USD 19.27. That consensus target is slightly below the USD 19.50 mean highlighted in other data, but both figures point to a modest expected appreciation versus the USD 17.89 trading level and remain below the USD 21.01 implied takeover value referenced in the Kimberly-Clark deal terms.
Risks and deal execution considerations
For investors in Kenvue stock, the main risk factor connected to the acquisition is that the ultimate consideration depends on Kimberly-Clark's share price when the transaction closes. As 24/7 Wall St points out, the implied per-share value of around USD 21.01 from the initial announcement fluctuates with Kimberly-Clark's trading level, meaning that a weaker Kimberly-Clark share price at closing would reduce the stock portion of the payout. In addition, the transaction still needs to pass through the usual regulatory and closing conditions, so timing and structure could be subject to adjustment.
Operationally, Kenvue's ability to sustain its brands and margins is another risk element that feeds back into valuation. The company positions itself as a consumer health leader with a differentiated brand portfolio that includes names such as Aveeno, Band-Aid, Johnson's, Listerine, Neutrogena, Nicorette, Tylenol and Zyrtec, as described by 24/7 Wall St. Any slowdown in demand across these categories, competitive price pressure or regulatory shifts affecting over-the-counter medicines and consumer products could weigh on revenue and profitability, and thereby on both standalone valuation and the strategic logic of the deal.
Stock price level and trading metrics
On the market-data side, Kenvue stock shows a combination of modest price movement and income characteristics that attract yield-oriented investors. According to Yahoo Finance, the Kenvue share price of USD 17.89 as of 2:38 p.m. Eastern Time on September 18, 2026 represented a gain of USD 0.06 or 0.31 percent versus the previous close of USD 17.83. The same data indicate that the stock opened the session at USD 17.98, suggesting that it has traded within a relatively tight intraday range around the mid-USD 17 level.
For context, the forward dividend yield of 4.71 percent mentioned earlier translates into a cash payout of USD 0.84 per share per year, and according to Yahoo Finance the next ex-dividend date for Kenvue is September 21, 2026. This schedule means that investors holding Kenvue shares through that date would be entitled to the upcoming dividend payment. For long-term investors, the combination of a high-single-digit implied upside to analyst targets, a takeover premium scenario and a dividend yield above 4 percent make the stock a blend of income and corporate action exposure rather than a pure growth story.
Kenvue stock at a glance
- Company: Kenvue Inc.
- ISIN: US49177J1025
- Ticker: KVUE
- Trading venue: NYSE
- Price (as of September 18, 2026, 14:38): 17.89 USD
- Market capitalization: [value not provided in available data] USD (as of September 18, 2026)
- Sector / Industry: Consumer health / Household products
- Index membership: Not a member of a major headline index such as S&P 500
- Next earnings date: November 5, 2026
